The Shift from Palliative Care to⁤ Curative Therapies

For decades, many hereditary ⁣and acquired‍ sight-threatening diseases were considered largely untreatable, managed primarily with palliative ⁤care. However,‌ a new frontier ‍in medicine is emerging, offering increasingly targeted and ‌long-lasting solutions thru gene therapy. This ⁢shift was a key topic of discussion at the Italian society of Ophthalmological Sciences⁢ (SISO)-Italian Association ‍of Ophthalmologists (AIMO) congress in Rome, held in october‌ 2023.

Hereditary Retinal Dystrophies:⁢ A Genetic Challenge

Hereditary⁤ retinal⁣ dystrophies encompass a group of rare ​genetic diseases that affect the retina, leading to ​vision loss. These conditions,such‍ as Leber congenital‍ amaurosis ​(LCA), are often caused by a single genetic defect. the rarity ‌of these conditions has historically hindered research and treatment⁤ development.

According to the National Association for‍ Rare⁤ Disorders (NORD), retinal dystrophies affect approximately 1 ⁤in 4,000 people. The specific genetic mutations responsible for these diseases⁢ are diverse, presenting a⁣ complex challenge ​for therapeutic intervention.

Luxturna: A ⁣Landmark Achievement

The⁤ most significant example of⁣ success in this field⁤ is Luxturna (voretigene neparvovec-rzyl), a gene therapy approved ‍by‌ the U.S.Food and ‌Drug Administration (FDA) ⁢in ⁣December 2017.Luxturna targets ⁢a specific genetic⁤ mutation​ in individuals with LCA ‌caused by mutations in the RPE65 gene.

The treatment involves a single subretinal injection​ of ‍a viral vector carrying a functional‍ copy of ‍the RPE65 gene.⁤ Clinical‍ trials ​have demonstrated that Luxturna can restore ⁣visual function in children and ⁢young adults⁤ with⁢ this specific form of LCA. ​A FDA press release detailing the approval‌ highlights the ⁤significant advancement in⁢ functional vision observed in trial participants.